AIM Platform
Psoriasis
Key Facts
About Phaim Pharma
Phaim Pharma is a clinical-stage biotech pioneering Antigenic Immune Modulation (AIM), a platform designed to reset the immune system to cure or halt autoimmune diseases. Its lead program targets Type 1 Diabetes (T1D), a condition with significant unmet need and no current disease-modifying therapies. Backed by a leadership team with deep expertise in immunology and drug development, Phaim is positioning itself to address a large and growing autoimmune market. The company is privately held, pre-revenue, and has secured non-dilutive funding and awards to advance its research.
View full company profileAbout Phaim Pharma
Phaim Pharma is a clinical-stage biotech pioneering Antigenic Immune Modulation (AIM), a platform designed to reset the immune system to cure or halt autoimmune diseases. Its lead program targets Type 1 Diabetes (T1D), a condition with significant unmet need and no current disease-modifying therapies. Backed by a leadership team with deep expertise in immunology and drug development, Phaim is positioning itself to address a large and growing autoimmune market. The company is privately held, pre-revenue, and has secured non-dilutive funding and awards to advance its research.
View full company profileAbout Phaim Pharma
Phaim Pharma is a clinical-stage biotech pioneering Antigenic Immune Modulation (AIM), a platform designed to reset the immune system to cure or halt autoimmune diseases. Its lead program targets Type 1 Diabetes (T1D), a condition with significant unmet need and no current disease-modifying therapies. Backed by a leadership team with deep expertise in immunology and drug development, Phaim is positioning itself to address a large and growing autoimmune market. The company is privately held, pre-revenue, and has secured non-dilutive funding and awards to advance its research.
View full company profileOther Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Autoimmune psoriasis candidate | Nyrada | Preclinical |
| CYPS317 | FibroBiologics | Discovery |
| PEP Biologic™ | Intent Biologics | Unknown |
| DMT410 | Dermata Therapeutics | Preclinical |
| IL23R program | Acellera | Pre-clinical |
| Undisclosed Psoriasis Program | Nepsone | Preclinical |
| TEM-1657 (Topical) | Temisis | Pre-clinical |
| TEM-1657 (Oral) | Temisis | Pre-clinical |
| orismilast | UNION therapeutics | Phase 2 |
| Laikangqita Monoclonal Antibody | Livzon Pharmaceutical | NDA |
| CT-P55 | Celltrion | Phase 3 |
| JNJ-77242113 | Johnson & Johnson | Phase 3 |